Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. MCI Onehealth Technologies Inc.
  6. News
  7. Summary
    DRDR   CA58118M1086

MCI ONEHEALTH TECHNOLOGIES INC.

(DRDR)
  Report
Delayed Toronto Stock Exchange  -  02:54 2022-11-30 pm EST
0.5400 CAD   -1.82%
11/14Transcript : MCI Onehealth Technologies Inc., Q3 2022 Earnings Call, Nov 14, 2022
CI
11/14MCI Onehealth Technologies Inc. Provides Revenue Guidance for the Year 2022
CI
11/14MCI Onehealth Third Quarter Financial Results
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

MCI Onehealth and Euclid Telehealth Collaborate to Improve Patient Vision Outcomes Through Data-Driven Screening

08/12/2022 | 12:03pm EST

MCI Onehealth Technologies Inc. and Euclid Telehealth, are collaborating to increase access to care that can curtail and potentially prevent vision loss among Ontario patients. The approach contributes to improved health outcomes, better quality of life and significant cost avoidance for the healthcare system. MCI is using its data insights infrastructure to help family physicians identify patients within their practices that might be at risk for eye disease. Patients are then contacted by MCI to confirm their interest in attending a diagnostic session provided by Euclid at the MCI clinic. Euclid brings its portable diagnostic equipment and expert Ophthalmologists. This physician-directed care pathway is so convenient and personalized that it encourages patient uptake of the service, with MCI and Euclid seeing up to 20 patients at each screening day. After the eye health assessment, Euclid ophthalmologists coordinate with the patient and their MCI physician for further appropriate monitoring, or any follow up care with a local optometrist or ophthalmologist. To date, hundreds of patients have gone through the program, including several for whom blindness might be prevented. Euclid-
day clinics MCI sites happen based on patient need, currently occurring about once per week at multiple sites. Additionally, MCI and Euclid promote awareness of the risk factors and diagnostic options to potential patients outside of the MCI network and among MCI staff and physicians, such that even first-time patients with appropriate risk factors can be flagged and offered the right care pathway. Prevention of eye disease is an important health and economic initiative 1 in 5 Canadians will develop significant, preventable, vision loss in their lifetime; More than 8 million Canadians are currently living with eye disease from one of the four defined main conditions, of which, 1.2 million have vision loss from their disease. The prevalence of eye disease doubles every decade over the age of 40, which underscores the need for vision screening, Increasing prevalence of vision loss for patients leads to increased falls, motor vehicle accidents, depression, loss of mobility, and earlier death. There is a 29% higher risk of mortality for those with vision loss compared to those with unimpaired vision. It is estimated that the total cost of vision loss in Canada was $32.9 billion in 2019, and is expected to grow to $56 billion by 2050. Approximately 71% of the total costs (wellbeing & healthcare system) due to vision loss are preventable. With screening and early diagnosis, disease progression and vision loss often can be curtailed for prevalent eye diseases, including: Age related macular degeneration (AMD), which left untreated leads to blindness Cataracts Diabetic Retinopathy (DR) a complication of diabetes Glaucoma, a group of diseases that, while initially asymptomatic, damage the eye's optic nerve and results in blindness. MCI's collaboration with Euclid is another example of MCI's data-driven approach making a real impact for actual patients: disease screening, quick referral to specialists and personalized treatment. This approach helps identify, treat and monitor illness before it can further progress, creating economic savings on many levels. Similar data-driven programs are under way within the MCI network related to other speciality areas.


ę S&P Capital IQ 2022
All news about MCI ONEHEALTH TECHNOLOGIES INC.
11/14Transcript : MCI Onehealth Technologies Inc., Q3 2022 Earnings Call, Nov 14, ..
CI
11/14MCI Onehealth Technologies Inc. Provides Revenue Guidance for the Year 2022
CI
11/14MCI Onehealth Third Quarter Financial Results
GL
11/14MCI Onehealth Third Quarter Financial Results
GL
11/14MCI Onehealth Technologies Inc. Reports Earnings Results for the Third Quarter and Nine..
CI
11/07MCI Onehealth Announces Date of ItsáThird Quarter 2022 Earnings Call
GL
11/07MCI Onehealth Announces Date of ItsáThird Quarter 2022 Earnings Call
AQ
10/04MCI Onehealth Expanding Data Insights Offering with AI-driven Continuing Medical Educat..
MT
10/04MCI Onehealth Expands Data Insights Offering with Innovative AI-driven Continuing Medic..
GL
10/04MCI Onehealth Expands Data Insights Offering with Innovative AI-driven Continuing Medic..
AQ
More news
Financials
Sales 2022 54,7 M 40,4 M 40,4 M
Net income 2022 -20,2 M -14,9 M -14,9 M
Net Debt 2022 5,74 M 4,24 M 4,24 M
P/E ratio 2022 -1,38x
Yield 2022 -
Capitalization 27,5 M 20,3 M 20,3 M
EV / Sales 2022 0,61x
EV / Sales 2023 0,56x
Nbr of Employees 400
Free-Float 16,5%
Chart MCI ONEHEALTH TECHNOLOGIES INC.
Duration : Period :
MCI Onehealth Technologies Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MCI ONEHEALTH TECHNOLOGIES INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 0,55 CAD
Average target price 1,20 CAD
Spread / Average Target 118%
EPS Revisions
Managers and Directors
Alexander Dobranowski Chief Executive Officer & Executive Director
Scott Nirenberski Chief Financial Officer & Secretary
George Christodoulou Co-Executive Chairman
Sven F. Grail Co-Executive Chairman
Jennifer Foster Chief Operating Officer
Sector and Competitors